StockData
Denali Therapeutics Inc. logo

Denali Therapeutics Inc. (DNLI) stock

DNLINasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 6/30
$18.40+0.40 (+2.22%)

Close on Nov 18, 2026Market cap $2.94BP/E –Yield –

Denali Therapeutics price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Denali Therapeutics's price to sales ratio was 11.8× on Jul 31, 2024, against 38.3× a year earlier. Over the last 5 years it ranged from 6.5× to 426.7×, with a median of 28.9×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2024Jul 31, 202411.8×+3.1
2023Dec 29, 20238.7×−22.4
2022Dec 30, 202231.1×+15.7
2021Dec 31, 202115.4×−411.3
2020Dec 31, 2020426.7×+415.4
2019Dec 31, 201911.3×–

More Denali Therapeutics figures

See a number that looks wrong?